Skip to content

NASDAQ · small · thesis board

EDIT Editas Medicine

CRISPR gene-edited HSC therapy (reni-cel)

View race

Thesis

Editorial summary — not a primary filing

Reni-cel SCD program aiming to catch gene-editing leaders with updated datasets.

Next gate

2026-09-20Company-guidedPh2 readout

Updated SCD dataset

38 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~12 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~395d)100%
Days to gate (38d)10%
Show math

$260M cash ÷ $20M/mo burn ≈ 395 days. Source: curated SEC quarter figures.

Cash $260M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
CRSPApprovedokBLUEApprovedokBEAMPh1ok

Risks

  • Lag vs approved peers
  • Clinical differentiation
  • Financing
  • Platform focus

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT04853576as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01